Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H11N2O3.Na |
| Molecular Weight | 230.1957 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)CCCNC(=O)C1=CN=CC=C1
InChI
InChIKey=DGWZSECHAXUHPD-UHFFFAOYSA-M
InChI=1S/C10H12N2O3.Na/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8;/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H11N2O3 |
| Molecular Weight | 207.2059 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Picamilon (also known as N-nicotinoyl-GABA, Pycamilon, and Pikamilon) is a drug formed by a synthetic combination of niacin and GABA. It was developed in the Soviet Union in 1969 and further studied in both Russia and Japan as a prodrug of GABA. Picamilon permeated the blood-brain barrier and then is hydrolyzed into GABA and niacin. The released GABA, in theory, would activate GABA receptors potentially producing an anxiolytic response. The second released component, niacin, is a vasodilator. Today picamilon is sold in Russia as a prescription drug and is used for the treatment of a variety of illnesses and disorders, ranging from depression to a migraine, neuro infections, senile psychosis, certain types of glaucoma, and even acute alcohol intoxication. As of 2015, the FDA classified picamilon as a substance that does not meet the requirements of a dietary supplement and is therefore no longer permitted to be sold in the United States.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2093872 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Пикамилон Approved UseIndication of the drug Picamylon
Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function). |
|||
| Primary | Пикамилон Approved UseIndication of the drug Picamylon
Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function). |
|||
| Primary | Пикамилон Approved UseIndication of the drug Picamylon
Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function). |
|||
| Primary | Пикамилон Approved UseIndication of the drug Picamylon
Violations of cerebral circulation (acute ischemic, subacute and recovery periods of ischemic stroke, chronic cerebral circulatory failure), vegetovascular dystonia, asthenia, depression, senile psychosis; alcoholism (the period of withdrawal), acute alcohol intoxication, migraine, craniocerebral trauma, neuroinfections, primary open-angle glaucoma (for stabilization of visual function). |
Sample Use Guides
cerebrovascular diseases - 0,02-0,05 g 2-3 times for 1-2 months;
depression - on 0,04-0,2 g in 2-3 receptions in day within 1,5-3 months;
as an anti-asthenic and tranquilizing agent - 0,04-0,08 g per day, in some cases - up to 0,2-0,3 g per day for 1-1,5 months;
alcoholism: 0.1-0.15 g per day (course - 6-7 days)
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:06:09 UTC 2023
by
admin
on
Sat Dec 16 08:06:09 UTC 2023
|
| Record UNII |
S4L664E11D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60212142
Created by
admin on Sat Dec 16 08:06:09 UTC 2023 , Edited by admin on Sat Dec 16 08:06:09 UTC 2023
|
PRIMARY | |||
|
S4L664E11D
Created by
admin on Sat Dec 16 08:06:09 UTC 2023 , Edited by admin on Sat Dec 16 08:06:09 UTC 2023
|
PRIMARY | |||
|
62936-56-5
Created by
admin on Sat Dec 16 08:06:09 UTC 2023 , Edited by admin on Sat Dec 16 08:06:09 UTC 2023
|
PRIMARY | |||
|
23663986
Created by
admin on Sat Dec 16 08:06:09 UTC 2023 , Edited by admin on Sat Dec 16 08:06:09 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|